Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial.

@article{Verstraete2012LithiumLE,
  title={Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial.},
  author={Esther Verstraete and Jan Herman Veldink and Mark Huisman and Tim Draak and Esther V. Uijtendaal and Anneke Jelly van der Kooi and Helenius Jurgen Schelhaas and Marianne de Visser and Ingeborg van van der Tweel and Leonard H van den Berg},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  year={2012},
  volume={83 5},
  pages={557-64}
}
OBJECTIVES To determine the safety and efficacy of lithium for the treatment of amyotrophic lateral sclerosis (ALS) in a randomised, placebo controlled, double blind, sequential trial. METHODS Between November 2008 and June 2011, 133 patients were randomised to receive lithium carbonate (target blood level 0.4-0.8 mEq/l) or placebo as add-on treatment with riluzole. The primary endpoint was survival, defined as death, tracheostomal ventilation or non-invasive ventilation for more than 16 h… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…